Detailed narrative
Idaho Falls Divestiture and Strategic Rationale
The company announced the sale of its interest in the Idaho Falls market (Mountain View Hospital and Idaho Falls Community Hospital) for approximately $795 million in gross proceeds. This transaction represents the vast majority of planned portfolio optimization, aiming to sharpen focus on core short-stay surgical facilities, simplify operations, drive growth, and strengthen the balance sheet. The Idaho Falls facilities had evolved beyond short-stay surgical focus to include traditional acute care services, making them more complex and capital-intensive than the rest of the portfolio.
Financial Impact of Divestiture
The $795 million gross proceeds represent approximately 7x LTM adjusted EBITDA for Idaho Falls, or 17x the distributions received over the past three years, reflecting the high capital intensity of these assets. The transaction is expected to reduce consolidated debt and lower balance sheet leverage by approximately 0.3 turns. Historically, excluding Idaho Falls, Q2 FY26 revenue would have been $660 million and adjusted EBITDA $98 million, providing a clearer view of the go-forward company profile.
Q2 FY26 Performance Highlights
Surgery Partners reported net revenue of $849 million, up 2.7% year-over-year, and adjusted EBITDA of $125 million, both exceeding expectations. Same-facility net revenue increased 5% year-over-year, driven by a 4.8% increase in net revenue per case, reflecting a focus on higher acuity orthopedic and vascular procedures. Same-facility cases increased 0.3%.
Payer Mix Dynamics
Commercial payer mix moderated to approximately 49% of net revenue in Q2, a 350 basis point decrease year-over-year, with a corresponding increase in government mix. This shift was primarily isolated to larger surgical hospitals and was consistent with full-year guidance assumptions, viewed as an expected revenue mix item rather than a change in underlying patient demand. The divestiture of Idaho Falls is expected to further reduce Medicaid exposure.
Physician Recruiting and De Novo Growth
The company recruited 191 new physicians in Q2, bringing the year-to-date total to 330. The initial revenue contribution from the 2026 cohort increased nearly 16% compared to the 2025 cohort, highlighting the compounding effect of recruiting. Additionally, 6 de novo facilities are under construction, with 7 more in the pipeline, representing important long-term growth opportunities.
M&A Strategy and Capital Allocation
While M&A activity has been immaterial year-to-date and the $200 million average annual investment target will not be met in 2026, the company maintains an active pipeline and remains disciplined. The focus is on strategic fit, return potential, and balance sheet objectives. Post-transaction, capital allocation will prioritize deleveraging, high-return organic growth, de novo development, and strategic acquisitions.
Cost Management and Operational Efficiency
Operating expenses, including salaries and wages and supplies, showed sequential improvement as a percentage of revenue from Q1 to Q2, reflecting seasonal revenue step-up and continued operating discipline. Management emphasized ongoing focus on cost management, labor, supplies, and eliminating systematic inefficiencies.